论文部分内容阅读
目的:观察大剂量氨溴索联合抗生素对肺部铜绿假单胞菌感染的治疗效果。方法:随机将2010年12月~2013年12月在石河子大学医学院第四附属医院ICU及呼吸内科住院的71例肺部铜绿假单胞菌感染患者分为两组,对照组36例,给予常规剂量氨溴索加抗生素治疗;受试组35例,给予大剂量氨溴索加抗生素治疗,疗程均为14 d,对比两组的感染严重程度控制情况及细菌清除情况。结果:1治疗后7 d、14 d,两组患者PCT、简化CPIS评分均有下降趋势,相比差异有统计学意义(P<0.001)。2受试组PCT浓度和CPIS在治疗第7天及第14天分别为(1.89±0.48)mg/L、(0.43±0.33)mg/L,(3.92±0.84)分和(1.69±0.67)分,均明显低于对照组(2.32±0.89)mg/L、(0.66±0.45)mg/L,(4.29±0.57)分和(2.17±0.79)分(t=2.543、2.476、2.156、2.759,均P<0.05))。3受试组与对照组分别有22例、14例铜绿假单胞菌被清除,细菌清除率各为62.19%、38.9%,两组比较差异有统计学意义(χ2=4.079,P<0.05)。结论:大剂量氨溴索联合抗生素有助于控制肺部铜绿假单胞菌感染,较常规剂量更有助于清除铜绿假单胞菌。
Objective: To observe the therapeutic effect of high-dose ambroxol combined antibiotics on pulmonary Pseudomonas aeruginosa infection. Methods: Seventy-one patients with Pseudomonas aeruginosa pulmonary infection who were hospitalized in the ICU and Respiratory Department of the Fourth Affiliated Hospital of Shihezi University School of Medicine from December 2010 to December 2013 were randomly divided into two groups. The control group received 36 The routine dose of ambroxol antibiotics treatment; 35 patients in the test group, given large doses of ambroxol antibiotics, the course of treatment were 14 d, comparing the two groups of infection severity control and bacterial clearance. Results: After 7 days and 14 days, both PCT and simplified CPIS scores decreased in both groups, with significant difference (P <0.001). 2 The PCT concentration and CPIS in the test group were (1.89 ± 0.48) mg / L, (0.43 ± 0.33) mg / L, (3.92 ± 0.84) and (1.69 ± 0.67) on the 7th and 14th day (2.32 ± 0.89) mg / L, (0.66 ± 0.45) mg / L, (4.29 ± 0.57) and (2.17 ± 0.79) respectively in the control group (t = 2.543,2.476,2.156,2.759, both P <0.05)). There were 22 cases of Pseudomonas aeruginosa and 14 cases of Pseudomonas aeruginosa in the test group and the control group respectively. The bacterial clearance rates were 62.19% and 38.9% respectively, with significant difference between the two groups (χ2 = 4.079, P <0.05) . CONCLUSIONS: High-dose ambroxol combined with antibiotics can help control pulmonary Pseudomonas aeruginosa infections and is more amenable to the removal of Pseudomonas aeruginosa than conventional doses.